Verona Pharma plc (I9SA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verona Pharma plc (I9SA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€30.56 Million ≈ $35.73 Million USD) by net assets (€278.27 Million ≈ $325.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Verona Pharma plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Verona Pharma plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Verona Pharma plc carry for a breakdown of total debt and financial obligations.
Verona Pharma plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agree Realty Corporation
NYSE:ADC
|
0.023x |
|
Allegro Microsystems Inc
NASDAQ:ALGM
|
0.037x |
|
CubeSmart
NYSE:CUBE
|
0.049x |
|
Hella KGaA Hueck & Co
XETRA:HLE
|
0.175x |
|
MISC Bhd
KLSE:3816
|
0.038x |
|
Bangkok Dusit Medical Services Public Company Limited
BK:BDMS
|
0.039x |
|
Brenntag SE
F:BNR
|
0.076x |
|
Localiza Rent a Car S.A
SA:RENT3
|
0.047x |
Annual Cash Flow Conversion Efficiency for Verona Pharma plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma plc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Verona Pharma plc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €204.56 Million ≈ $239.15 Million |
€-122.20 Million ≈ $-142.87 Million |
-0.597x | -196.53% |
| 2023-12-31 | €249.28 Million ≈ $291.44 Million |
€-50.22 Million ≈ $-58.71 Million |
-0.201x | +22.44% |
| 2022-12-31 | €230.47 Million ≈ $269.44 Million |
€-59.86 Million ≈ $-69.98 Million |
-0.260x | -15.61% |
| 2021-12-31 | €148.00 Million ≈ $173.03 Million |
€-33.25 Million ≈ $-38.88 Million |
-0.225x | +7.86% |
| 2020-12-31 | €184.85 Million ≈ $216.11 Million |
€-45.08 Million ≈ $-52.70 Million |
-0.244x | +74.74% |
| 2019-12-31 | €44.40 Million ≈ $51.91 Million |
€-42.87 Million ≈ $-50.12 Million |
-0.965x | -325.69% |
| 2018-12-31 | €79.86 Million ≈ $93.36 Million |
€-18.11 Million ≈ $-21.17 Million |
-0.227x | -18.30% |
| 2017-12-31 | €107.95 Million ≈ $126.21 Million |
€-20.70 Million ≈ $-24.20 Million |
-0.192x | -45.96% |
| 2016-12-31 | €42.53 Million ≈ $49.72 Million |
€-5.59 Million ≈ $-6.53 Million |
-0.131x | -- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more